5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

Neuropsychopharmacology. 2023 Aug;48(9):1257-1266. doi: 10.1038/s41386-023-01572-w. Epub 2023 Apr 4.

Abstract

Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-lived subjective effects may be clinically useful because dosing time would be reduced, which may improve patient access. One short-acting psychedelic is 5-MeO-DMT, which has been associated with improvement in depression and anxiety symptoms in early phase clinical studies. However, relatively little is known about the behavioral and neural mechanisms of 5-MeO-DMT, particularly the durability of its long-term effects. Here we characterized the effects of 5-MeO-DMT on innate behaviors and dendritic architecture in mice. We showed that 5-MeO-DMT induces a dose-dependent increase in head-twitch response that is shorter in duration than that induced by psilocybin at all doses tested. 5-MeO-DMT also substantially suppresses social ultrasonic vocalizations produced during mating behavior. 5-MeO-DMT produces long-lasting increases in dendritic spine density in the mouse medial frontal cortex that are driven by an elevated rate of spine formation. However, unlike psilocybin, 5-MeO-DMT did not affect the size of dendritic spines. These data provide insights into the behavioral and neural consequences underlying the action of 5-MeO-DMT and highlight similarities and differences with those of psilocybin.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Hallucinogens*
  • Instinct
  • Mental Disorders* / drug therapy
  • Methoxydimethyltryptamines / pharmacology
  • Mice
  • Psilocybin

Substances

  • Psilocybin
  • Hallucinogens
  • Methoxydimethyltryptamines